Provider Briefing: Revumenib Access in 2026

Revumenib (brand name Revuforj), the first FDA-approved menin inhibitor, has become an essential treatment option for patients with relapsed or refractory acute leukemia harboring KMT2A translocations and, as of October 2025, NPM1 mutations. However, prescribers continue to face challenges in getting this medication to their patients efficiently.

This article provides a concise overview of the current availability landscape, prescribing considerations, cost and access dynamics, and tools that can help streamline the process for your practice in 2026.

Timeline: From Approval to Present

Understanding Revumenib's regulatory history helps contextualize the current access environment:

• November 2024 — FDA approval for relapsed or refractory acute leukemia with a KMT2A translocation in adults and pediatric patients ≥1 year old. 110 mg and 160 mg tablets available at launch.
• Q1-Q2 2025 — 25 mg pediatric tablets become commercially available. Prior to this, an oral solution was available for patients under 40 kg.
• October 2025 — FDA expands indication to include relapsed or refractory AML with a susceptible NPM1 mutation in patients with no satisfactory alternative treatment options.
• February 2026 — No formal shortage listed on FDA or ASHP databases, but limited specialty distribution continues to create access delays.

Revumenib received Breakthrough Therapy, Fast Track, Priority Review, and Orphan Drug designations from the FDA — reflecting both the urgency of the unmet need and the small patient population.

Prescribing Implications

Dosing Considerations

Revumenib dosing is weight-based and influenced by concomitant CYP3A4 inhibitor use:

• Patients ≥40 kg without strong CYP3A4 inhibitors: 270 mg orally twice daily
• Patients ≥40 kg with strong CYP3A4 inhibitors: 160 mg orally twice daily
• Patients <40 kg without strong CYP3A4 inhibitors: 160 mg/m² orally twice daily
• Patients <40 kg with strong CYP3A4 inhibitors: 95 mg/m² orally twice daily

Tablets should be taken fasting or with a low-fat meal (≤400 calories, ≤25% fat). Do not initiate until WBC is below 25 Gi/L. Minimum treatment duration is 6 months for patients without disease progression.

Boxed Warnings

The prescribing information includes boxed warnings for:

• Differentiation syndrome — If suspected, initiate systemic corticosteroids immediately (Dexamethasone 10 mg IV q12h in adults; 0.25 mg/kg/dose IV q12h in children <40 kg)
• QTc prolongation and Torsades de Pointes — Obtain ECG prior to initiation, weekly for 4 weeks, then monthly. Do not initiate if QTcF >450 msec. Correct electrolyte abnormalities before and during treatment.

Key Drug Interactions

Revumenib is primarily metabolized by CYP3A4. Key interactions include:

• Strong CYP3A4 inhibitors (Posaconazole, Itraconazole, Voriconazole, Cobicistat) — Require dose reduction as noted above
• Strong/moderate CYP3A4 inducers — Avoid concomitant use; may decrease Revumenib exposure and increase M1 metabolite-related QT prolongation risk
• QTc-prolonging medications — Avoid if possible; if concomitant use is unavoidable, increase ECG monitoring frequency

For a patient-facing overview of interactions, see: Revumenib drug interactions: What to avoid.

Current Availability Picture

Revumenib is distributed exclusively through specialty pharmacies. It is not available at retail pharmacies. The limited distribution model reflects both the drug's high cost (WAC: ~$39,500/month) and the clinical monitoring requirements (ECG surveillance, differentiation syndrome vigilance).

As of early 2026:

• No formal shortage is reported on FDA or ASHP databases
• Specialty pharmacy networks are operational but turnaround times vary
• Prior authorization remains a significant bottleneck for many patients
• The expanded NPM1 indication has increased the eligible patient pool, which may further strain distribution capacity

Cost and Access

Pricing

• WAC: ~$39,500 per month (~$474,000 annually)
• No generic available
• Copay program: Eligible commercially insured patients may pay $0 through the Revuforj Copay Program via SyndAccess

Insurance Considerations

Most commercial and government payers require prior authorization. Documentation needed typically includes:

• Confirmed KMT2A translocation or NPM1 mutation via FDA-authorized testing
• Documentation of relapsed or refractory disease
• For NPM1 indication: evidence that no satisfactory alternative treatment options exist

Some payers may impose step therapy requirements. Appeals support is available through SyndAccess.

Tools and Resources for Providers

SyndAccess

Syndax Pharmaceuticals' support program offers:

• Insurance verification and prior authorization support
• Specialty pharmacy coordination
• Patient copay assistance
• Nurse navigator support
• Phone: 1-888-567-SYND (7963), Monday-Friday, 8 AM-8 PM ET
• Enrollment forms available at revuforjhcp.com

Medfinder for Providers

Medfinder allows providers to check real-time availability of specialty medications across pharmacy networks. This can be especially useful when patients are facing delays and need to identify alternative dispensing options quickly.

Prescribing Resources

• Full Prescribing Information
• Medication Guide and Instructions for Use

Looking Ahead

The menin inhibitor pipeline continues to expand. Several other agents are in clinical development:

• Ziftomenib — Late-stage trials; potential FDA submission anticipated
• Bleximenib (JNJ-75276617) — Johnson & Johnson; in clinical trials for KMT2A-rearranged leukemia
• Enzomenib (DSP-5336) — Being evaluated as monotherapy and in combination

Additional approvals in this class could expand treatment options and reduce the access burden currently concentrated on Revumenib as the sole approved agent.

Combination studies — including Revumenib with standard chemotherapy backbones — are also underway and may reshape treatment paradigms for KMT2A-rearranged and NPM1-mutated acute leukemia in the coming years.

Final Thoughts

Revumenib represents a significant therapeutic advance for patients with KMT2A-rearranged and NPM1-mutated acute leukemia. However, the current specialty distribution model, combined with prior authorization requirements and high costs, creates access challenges that require proactive management from prescribers.

Leveraging SyndAccess for patient enrollment, using tools like Medfinder to check availability, and staying informed about the evolving menin inhibitor landscape will help ensure your patients get the treatment they need as efficiently as possible.

For a patient-friendly guide to help your patients navigate access, see: How to help your patients find Revumenib in stock.